Chronic B-Cell Leukemia (CBCL) Treatments
Find Chronic B-Cell Leukemia (CBCL) Treatments
Medications for Chronic B-Cell Leukemia (CBCL)
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Chronic B-Cell Leukemia (CBCL).
Found 10 Approved Drugs for Chronic B-Cell Leukemia (CBCL)
RiTUXimab
Brand Names
Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima
RiTUXimab
Brand Names
Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: November 26, 1997
Classification: CD20-directed Cytolytic Antibody
RIABNI is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL).
Fludarabine
Generic Name
Fludarabine
Fludarabine
Generic Name
Fludarabine
Form: Injection
Method of administration: Intravenous
FDA approval date: November 16, 2007
Classification: Nucleoside Metabolic Inhibitor
Fludarabine Phosphate Injection, USP is indicated for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. The safety and effectiveness of Fludarabine Phosphate Injection, USP in previously untreated or non-refractory patients with CLL have not been established.
Imbruvica
Generic Name
Ibrutinib
Imbruvica
Generic Name
Ibrutinib
Form: Tablet, Suspension, Capsule
Method of administration: Oral
FDA approval date: November 13, 2013
Classification: Kinase Inhibitor
IMBRUVICA is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL).
Bendamustine
Brand Names
Belrapzo, Bendeka, Treanda, Vivimusta
Bendamustine
Brand Names
Belrapzo, Bendeka, Treanda, Vivimusta
Form: Injection
Method of administration: Intravenous
FDA approval date: March 31, 2008
Classification: Alkylating Drug
BELRAPZO is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.
Gazyva
Generic Name
Obinutuzumab
Gazyva
Generic Name
Obinutuzumab
Form: Injection
Method of administration: Intravenous
FDA approval date: November 01, 2013
Classification: CD20-directed Cytolytic Antibody
GAZYVA is a CD20-directed cytolytic antibody indicated: in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia. ( 1, 14 ) in combination with bendamustine followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen. ( 1, 14 ) in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma. ( 1, 14 )
Showing 1-5 of 10
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances